Place-Based Impact Investing: Harnessing Investment for Local Development
Papers
9 Apr 24

Place-Based Impact Investing: Harnessing Investment for Local Development

Our paper, “Place-Based Impact Investing: Harnessing Investment for Local Development”, explores how local impact investing can deliver social and environmental benefits alongside attractive returns.
Rooftop Solar: An Investment Case
Papers
7 Sep 23

Rooftop Solar: An Investment Case

Our paper, “Rooftop Solar: An Investment Case”, explores the key reasons to invest in solar energy, and in particular rooftop solar, which offers its own unique set of benefits for the energy transition and for investors.
Neuro-Bio Podcast: Episode 1
Podcasts
28 Mar 23

Neuro-Bio Podcast: Episode 1

Baroness Professor Susan Greenfield, CEO and founder at Neuro-Bio, Richard Mohs PHD and Dr Michal Zurawski discuss new insights from Alzheimer’s research and the work Clota Värde and Neuro-Bio are envisaging to develop pre-symptomatic testing and an effective cure.
4Life Solutions
Client Projects
16 Feb 23

4Life Solutions

4Life Solutions is a social impact company focused on providing clean water to low-income communities. Their solar water disinfection system, SaWa, offers a simple, efficient and climate-friendly alternative to boiling water using wood or charcoal.
At the Dawn of the Hydrogen Era
Papers
8 Feb 23

At the Dawn of the Hydrogen Era

Our paper, “At the Dawn of the Hydrogen Era”, explains how hydrogen can assist in the clean energy transition, particularly in sectors which are difficult to decarbonise, such as heavy industry and transport.
Clota Varde and ESG
Podcasts
7 Feb 23

Clota Varde and ESG

We meet Alexandra Martinez, Co-founder of Clota Varde. Their mission is to mobilise institutional investment into companies and organisations that are built on strong foundations of social purpose and environmental responsibility.
Neuro-Bio
Client Projects
7 Feb 23

Neuro-Bio

Neuro-Bio is a privately-owned UK biotech company out of Oxford University. Its unique value proposition is based on its identification of the pivotal mechanism leading to the neurodegeneration that characterises Alzheimer’s disease.